Compositions of Human Prothrombin and Activated Factor X for Improving Hemostasis in the Treatment of Bleeding Disorders
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,160,850 | Compositions of Human Prothrombin and Activated Factor X for Improving Hemostasis in the Treatment of Bleeding Disorders In force · High confidence | Baxalta Incorporated and Baxalta GmbH | In force | High confidence | ||
| Application 14/658,006 | Compositions of Human Prothrombin and Activated Factor X for Improving Hemostasis in the Treatment of Bleeding Disorders Abandoned Abandoned Apr 4, 2019 | Baxalta Incorporated and Baxalta GmbH | Abandoned | Abandoned Apr 4, 2019 |
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Baxalta Incorporated.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.